SOST and osteoporosis: Romosozumab, a humanized monoclonal antibody used to treat osteoporosis, inhibits sclerostin, a molecule expressed by osteocytes and involved with inhibition of osteogenesis via Wnt/β-catenin pathway [162, 163].